FindTrial
Sign In

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-508284-77-00
Acronym
ALXN1720-MG-301
Enrollment
82
Registered
2024-05-13
Start date
2022-11-16
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

Brief summary

Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26

Detailed description

Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26, Percentage of Responders Based on Reduction of the MG-ADL Total Score at Week 26, Percentage of Responders based on Reduction of the QMG Total Score at Week 26, Change From Baseline in Myasthenia Gravis Composite (MGC) Total Score at Week 26, Change from Baseline in the QMG total score at Week 4

Interventions

DRUGGefurulimab
DRUGALXN1720 Placebo Product

Sponsors

Alexion Pharmaceuticals Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26—

Secondary

MeasureTime frame
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26, Percentage of Responders Based on Reduction of the MG-ADL Total Score at Week 26, Percentage of Responders based on Reduction of the QMG Total Score at Week 26, Change From Baseline in Myasthenia Gravis Composite (MGC) Total Score at Week 26, Change from Baseline in the QMG total score at Week 4—

Countries

Austria, Denmark, France, Germany, Italy, Netherlands, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026